Table IV.
Distribution of the 4G/5G polymorphism in remission and progression patients.
| Remissor, n (%) | Progressor, n (%) | OR (95% CI) | P-valuea | |
|---|---|---|---|---|
| Genotype | ||||
| 4G/4G | 4 (11.4) | 8 (38.1) | 5.23 (1.34–20.38) | 0.0183 |
| 4G/5G | 22 (54.3) | 9 (42.9) | 0.55 (0.19–1.60) | 0.2681 |
| 5G/5G | 12 (34.3) | 4 (10.0) | 0.51 (0.14–1.85) | 0.3702 |
| Alleles | ||||
| 4G | 30 (39.5) | 25 (59.5) | 2.26 (1.05–4.87) | 0.0366 |
| 5G | 46 (60.5) | 17 (40.5) | 0.44 (0.21–0.96) |
a
Chi-square test or Fisher’s exact test; progressor vs. remissor in each analysis. OR, odds ratio; CI, confidence intervals; Remissor, patients with normal renal function and without hematuria and proteinuria; Progressor, patients with persistent hematuria and severe proteinuria (≥1,000 mg/day) and/or hypertension.